Mean change in YMRS from baseline at three weeks Young Mania Rating Scale (YMRS): an 11‐item questionnaire to assess the severity of core symptoms of mania. Scale from 0 to 60 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
1819 participants
Moderate
Barnes Akathisia Scale LOCF at week 12 A physician‐assessed rating scale to assess the severity of drug‐induced akathisia Scale from 0 to 14 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
646 participants
Low
Abnormal Involuntary Movement Scale LOCF at week 12 A physician‐administered rating scale with 12 items to measure tardive dyskinesia Scale from 0 to 40 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
634 participants
Low
Simpson Angus Scale LOCF at week 12 A physician‐administered rating scale to measure drug‐induced Parkinsonism Scale from 0 to 40. · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
646 participants
Low
≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) · patients with an acute manic or mixed episode
Aripiprazole probably leads to higher ≥ 50% decrease in total YMRS from baseline at three weeks Young… compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.7 [1.23, 2.34]
1230 participants
Moderate
Numbers completing double‐blind treatment Number of participants · patients with an acute manic or mixed episode
Aripiprazole showed no clear difference in numbers completing double‐blind treatment Number of participants compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.03 [0.95, 1.12]
2216 participants
Moderate
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High
Akathisia Participant report · patients with an acute manic or mixed episode
Aripiprazole leads to higher akathisia Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 3.16 [2.25, 4.43]
2305 participants
High
Nausea · patients with an acute manic or mixed episode
Aripiprazole leads to higher nausea Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 1.5 [1.2, 1.88]
2305 participants
High
Mean change in YMRS from baseline at three weeks Young Mania Rating Scale (YMRS): an 11‐item questionnaire to assess the severity of core symptoms of mania. Scale from 0 to 60 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
972 participants
Moderate
≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) · patients with an acute manic or mixed episode
Aripiprazole showed no clear difference in ≥ 50% decrease in YMRS from baseline at week three Young Mania… compared with other drug treatment (moderate certainty).
1 finding from 1 review
RR 1.12 [0.77, 1.63]
990 participants
Moderate
Numbers completing the trial (at end of week three) Number of participants · patients with an acute manic or mixed episode
Aripiprazole may leads to higher numbers completing the trial (at end of week three) Number of… compared with other drug treatment (low certainty).
1 finding from 1 review
RR 1.13 [1.03, 1.24]
994 participants
Low
Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia
COMPARISON 1. ARIPIPRAZOLE showed no clear difference in global state: No clinically significant response compared with CLOZAPINE (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether COMPARISON 2. ARIPIPRAZOLE changes leaving the study early compared with QUETIAPINE (very low certainty).
1 finding from 1 review
QoL · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether COMPARISON 2. ARIPIPRAZOLE changes adverse effects: extrapyramidal symptoms compared with QUETIAPINE (very low certainty).
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
COMPARISON 3. ARIPIPRAZOLE showed no clear difference in global state: No clinically significant response (as defined by the… compared with RISPERIDONE (low certainty).
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia
1 finding from 1 review